|
Originally published In Press as doi:10.1074/jbc.M109036200 on April 23, 2002
J. Biol. Chem., Vol. 277, Issue 27, 24148-24154, July 5, 2002
Impaired Protein Kinase C Activation/Translocation in
Epstein-Barr Virus-infected Monocytes*
Mélanie
Tardif,
Martin
Savard,
Louis
Flamand §, and
Jean
Gosselin¶
From the Laboratory of Viral Immunology, Laboratory
of Virology, Centre de Recherche en Rhumatologie et Immunologie, Centre
de Recherche du Centre Hospitalier de l'Université
Laval, and Université Laval, Québec
G1V 4G2, Canada
Received for publication, September 18, 2001, and in revised form, February 28, 2002
 |
ABSTRACT |
Infection of human monocytes by Epstein-Barr
virus (EBV) has been linked to a decrease in the production of
proinflammatory mediators as well as an impairment of phagocytosis.
Considering the key role of protein kinases C (PKCs) in many biological
functions of monocytes, including phagocytosis, we investigated the
effects of EBV on the PKC activity in infected monocytes. Our results indicate that infection of monocytes by EBV impairs both phorbol 12-myristate 13-acetate (PMA)-induced translocation of PKC isozymes and from cytosol to membrane as well as the PKC enzymatic activity.
Similarly, the subcellular distribution of the receptor for activated C
kinase (RACK), an anchoring protein essential to PKC translocation, was
also found to be reduced in EBV-infected monocytes. Transfection of
293T cells with an expression vector coding for the immediate-early
protein ZEBRA of EBV resulted in impaired PMA-induced translocation and
activity of PKC. Using co-immunoprecipitation assays, the ZEBRA protein
was found to physically interact with the RACK1 protein. Thus
interaction of ZEBRA with RACK likely results in the inhibition of PKC
activity, which in turn affects functions of monocytes, such as phagocytosis.
 |
INTRODUCTION |
Epstein-Barr virus
(EBV)1 is a human
-herpesvirus exhibiting a strong tropism for pharyngeal epithelial
cells and B lymphocytes. Some studies have shown that EBV infects other
cell types, including thymocytes (1), T lymphocytes (2), natural
killer cells (3) and Reed-Sternberg cells (4), which are found in
Hodgkin's disease. More recently, it has been reported that EBV
infects phagocytes such as neutrophils (5) and monocytes (6) and modulates their biological functions such as cytokine production (7)
and phagocytosis (6).
Involved in the clearance and destruction of microorganisms,
phagocytosis is an essential process for host defense. Hence, several
microorganisms have developed mechanisms to impair the phagocytic
ability of human monocytes. For example, it was reported that murine
cytomegalovirus (MCMV) (8) and human immunodeficiency virus (HIV) (9)
decrease the Fc receptor-mediated phagocytosis of IgG-opsonized
particles by a down-regulation of the Fc receptors expression.
Regarding EBV, the mechanisms by which this virus impairs phagocytosis
of human monocytes remain to be elucidated.
Phagocytosis is a complex process of particle ingestion involving the
recognition of a target by specific cell surface receptors and the
triggering of a signaling cascade, which allows the local reorganization of the actin-based cytoskeleton and internalization of
the foreign particle. Reports indicate that inhibition of PKCs causes a
decrease of phagocytosis by monocytes/macrophages (10-12). In
addition, several studies demonstrated that selected PKC isozymes interact with components of cytoskeleton such as F-actin (13), involved
in the engulfment of particles. In addition, PKC was found
associated with the phagosomal membranes, suggesting its importance in
the phagocytic process (10, 14). Furthermore, a recent study reported
that phagocytosis of latex beads by THP1 cells requires the activity of
both PKC and PKC , in support for a key role of these kinases in
this biological event (14).
Phosphorylation and translocation of PKCs are two essential steps for
activation of these enzymes (15-17). Previous reports have proposed
that localization of activated PKC in the membrane fractions following
agonist stimulation was mediated by the RACK (receptor for activated C
kinase) anchoring protein (18, 19). RACK1 is localized in a
specific organelle in resting cells and the activation of PKC leads a
movement of RACK1 to cell periphery (20). In fact, RACK1
co-localizes with the enzyme in response to PMA stimulation, a powerful
PKC activator (20). Recently it was reported that the HIV-1 Nef protein
binds to RACK1 and interferes with PKC activity in T lymphocytes
(21, 22). Interestingly, ZEBRA protein of EBV also binds RACK1 in
vitro (23). However, the effect of this association on PKC
activation remains undetermined. Thus, disruption of the association
between PKC and RACK1, which is essential to PKC activity, could
represent a strategy used by viruses to perturb cell signaling. Since
EBV decreases the phagocytic ability of monocytes and such function is
regulated in part by PKC, we investigated the possible mechanisms used
by EBV to alter the activation of PKC. For this purpose, we analyzed the enzymatic activity and translocation of PKC as well as the subcellular localization of RACK1 in infected monocytes. The current study demonstrates that infection of monocytes by EBV impairs the
activity and translocation of PKC / . Moreover, our results suggest
that such disruption of PKC translocation/activation is caused by the
ability of EBV-ZEBRA protein to interact with RACK.
 |
EXPERIMENTAL PROCEDURES |
Purification of Human Monocytes--
Peripheral blood
mononuclear cells were isolated by centrifugation of heparinized
blood obtained from healthy donors over a Ficoll-Hypaque gradient
(Amersham Biosciences, Uppsala, Sweden). Monocytes were enriched
by Percoll density centrifugation and purified (>98%) by cell sorting
(Epics Elite ESP, Coulter Electronics, Burlington, Ontario,
Canada). Cell viability was >99% as tested by trypan blue dye
exclusion procedure (6).
General Culture Conditions--
Purified human monocytes
(106 cells/ml) were cultured in RPMI 1640 medium
supplemented with 10% of heat inactivated fetal bovine serum and
cultured at 37 °C under 5% CO2 in 15-ml polypropylene tubes. The culture medium contained less than 10 pg/ml
endotoxin, as evaluated by Limulus amoebocyte assay
(Sigma). To evaluate the activity and translocation of PKC,
cells were stimulated with PMA (100 ng/ml) (Sigma) at 37 °C for
different periods of time.
Infection Procedure--
Viral preparations of EBV (strain
B95-8) were produced and titered as described previously (24).
Monocytes (2.5 × 106 cells) were incubated with
infectious EBV (105 transforming units) in 250 µl of
culture medium for 1 h at 37 °C and were washed twice in
Hanks' balanced salt solution (pH 7.4). Cells were subsequently
resuspended in 4 ml of culture medium and cultured for varying period
of times.
Phagocytosis Assay--
The phagocytic activity of EBV-infected
and uninfected monocytes was assessed by flow cytometry using
carboxylated fluoresceinated microspheres, as described previously (6).
Briefly, 5 × 105 monocytes were washed with 500 µl
of phosphate-buffered saline (pH 7.4) and resuspended in 350 µl of
Hanks' balanced salt solution supplemented with 5% fetal bovine
serum. Where indicated, cells were pretreated for 1 h with the
selective PKC inhibitor, calphostin C (500 nM) (Sigma) or
RO-31-8220 (500 nM) (Sigma), to inhibit phagocytosis.
Carboxylated fluoresceinated microspheres (1.87 µm: Fluoresbrite,
Polysciences, Warrington, PA) were added to give a ratio of 12 beads
per cell, and phagocytosis was allowed to proceed at 37 °C under
constant agitation (150 rpm) for 2 h. Subsequently, monocytes were
washed three times with 500 µl of cold phosphate-buffered saline to
remove unphagocytized microspheres and fixed in 500 µl of 0.5%
paraformaldehyde. Monocytes were analyzed with an EPICS-XL flow
cytometer and the percentage of fluorescent-positive monocytes determined.
Plasmid DNA Transfection--
The CMV-Z expression vector
contains the EBV-ZEBRA cDNA cloned downstream of the CMV
immediate-early promoter (kindly provided from Dr. Shannon Kenney,
University of North Carolina, Chapel Hill, NC). The human herpesvirus-6
IE1 expression plasmid was generated by the cloning of a full-length
IE1 cDNA into the pBK vector, as
described.2 Plasmid DNA was
transfected into embryonic 293T kidney cells using the EXGEN-500
reagent. Briefly, 2 µg of pCMV-Z or pHD1013 (empty vector) were added
to 200 µl of 150 mM NaCl and mixed with 400 µl of EXGEN
solution (12 µl of EXGEN reagent added to 400 µl of 150 mM NaCl) and left at room temperature for 5 min. The volumes were adjusted to 1600 µl with Dulbecco's modified Eagle's medium of which 800 µl of plasmid DNA were added in duplicated to
wells of six-well plates. Cells were incubated at 37 °C for 3 h
and then medium containing plasmid DNA/EXGEN was replaced with 3 ml of Dulbecco's modified Eagle's medium containing 10% fetal bovine
serum. Cells were incubated at 37 °C for an additional 12 h.
Preparation of Protein Fractions--
293T-transfected cells,
uninfected or EBV-infected monocytes (2 × 106 cells),
stimulated or not with PMA for 5 min were harvested and lysed in 500 µl of modified RIPA buffer (0.5% Nonidet P-40, 65 mM
Tris base (pH 7.4), 225 mM NaCl, 8 mM
Na3VO4, 1 mM NaF, 25 nM
calyculin A, 2 mM phenylmethylsulfonyl fluoride, 0.1 mg/ml aprotinin, and 0.1 mg/ml leupeptin) for 30 min on ice to obtain whole cell protein extracts. Cytosolic and membrane protein fractions were also obtained from PMA-stimulated monocytes and transfected 293T
cells. Briefly, 2 × 106 cells were resuspended in 200 µl of Hanks' balanced salt solution 1× and incubated in the absence
or in the presence of PMA (100 ng/ml) at 37 °C for 5 min. In some
experiments, cells were pretreated with calyculin A (10 nM), an inhibitor of protein serine/threonine phosphatases
PP1 and PP2A, 5 min before stimulation with PMA. Incubations were
stopped on ice followed by centrifugation of cell suspensions at
4 °C. Cells were resuspended in 100 µl of sonication buffer (20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 0.5 mM EGTA, 10 5 M
-mercaptoethanol, 25 µg/ml aprotinin, 25 µg/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride, 5 mM
sodium orthovanadate, 50 nM calyculin A, and 10 nM sodium fluoride) and then sonicated twice for 20 s.
The homogenates were spun at 10,000 × g for 10 min at
4 °C to pellet the nuclei. The supernatants were recovered and
ultracentrifuged at 100,000 × g for 45 min at 4 °C
to separate the cytosolic and membrane protein fractions. Membranes
were resuspended in sonicated buffer containing 2% Triton X-100.
Protein concentrations were determined using the BCA protein reagents (Pierce).
Immunoprecipitation--
Whole cell proteins from
293T-transfected cells (equivalent of 3 × 106 cells)
were incubated for 2 h with 2 µg of anti-ZEBRA (Argene, Varilhes, France) or with 2 µg of anti-PKC antibobies
(Transduction Laboratories, Lexington, NY) at 4 °C on a rotary
device. Fifty µl of immobilized protein G (Pierce) were added to the
samples and incubation continued overnight at 4 °C. Subsequently,
the samples were centrifuged and the pellets washed three times with phosphate-buffered saline. The bound proteins were eluted from the
beads by boiling in 2× Laemmli sample buffer for 7 min.
Electrophoresis and Immunoblotting--
Proteins were separated
by 9% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions followed by a transfer onto polyvinylidene fluoride
membranes (Immobilon-P, Millipore Corp., Bedford, MA). Membranes were
blocked using 5% (w/v) dry milk in Tris-buffered saline-Tween for 30 min at room temperature and then incubated for 1 h with
anti-PKC (1:250 diluted), anti-PKC (which reacts with both
1 and 2 isoforms) (1:200 diluted) (BD Transduction Laboratories, Missisauga, Ontario, Canada), anti-RACK1 (1:1000 diluted) (Santa Cruz, Santa Cruz, CA), or anti-ZEBRA (1:500 diluted) (Argene, Varilhes, France) antibodies. Membranes were washed
twice with Tris-buffered saline-Tween and incubated with either an
horseradish peroxidase-conjugated donkey anti-mouse IgG (1:5000
diluted) or donkey anti-rabbit IgG (1:10,000) (Jackson ImmunoResearch
Laboratories, West Grove, PA) for 1 h followed of three washes
with Tris-buffered saline-Tween. Immunoreactive proteins were revealed
using the enhanced chemiluminescence (ECL) Western blotting detection
system. The intensity of each signal was quantified by laser densitometry.
Protein Kinase C Assay--
Cytosolic and membrane fractions (50 µg for monocytes or 15 µg for 293T) from either uninfected,
EBV-infected monocytes, pHD1013-transfected 293T, or pCMV-Z-transfected
293T cells, untreated or PMA-treated, were assayed for PKC activity
using a commercial PKC assay system according to supplier's
recommendations (Upstate Biotechnology, Lake Placid, NY).
Statistical Analysis--
Statistical significance was
determined using unpaired two-tailed Student's test. A p
value of 0.05 was considered statistically significant.
 |
RESULTS |
Both EBV and PKC Inhibitors Decrease Phagocytosis of
Fluoresceinated Microspheres by Human Monocytes--
Considering that
phagocytosis is important for host defense, an impairment of this
function may lead to an increase susceptibility to infectious agents.
As shown in Fig. 1, EBV inhibits (by
40%) the ability of human monocytes to phagocyte fluoresceinated beads as reported previously (6). Phagocytosis triggering is often associated
with multimerization of cell surface receptors such as the Fc receptors
(CD32, CD64) and complement receptors (9, 25). As a first step, we
analyzed the expression of Fc RI (CD64), Fc RIIa (CD32), and CR3
(CD11b/CD18) on the cell surface of EBV-infected monocytes. Results
indicate that EBV has no effect on the expression of such molecules
(data not shown), suggesting that this virus impairs phagocytosis
through a yet to be defined mechanism. A previous study has reported
that activation of PKC is crucial for the phagocytosis of latex beads
and that pretreatment of THP-1 cells with specific PKC inhibitors
abolished this activity (14). To investigate the involvement of protein
kinases C on phagocytosis of latex beads by human monocytes, cells were
pretreated with specific PKC inhibitors (calphostin C and RO-31-8220)
and processed for phagocytosis assay. In agreement with a previous
study (14), our results (Fig. 1) show that pretreatment of monocytes
with PKC inhibitors decreases the ability of monocytes to ingest
microspheres, confirming the involvement of PKC in phagocytosis. Next,
we investigated the effects of EBV infection on PKC activation in
monocytes.

View larger version (8K):
[in this window]
[in a new window]
|
Fig. 1.
Suppression of phagocytosis by EBV and PKC
inhibitors. Monocytes (5 × 105cells) were
infected with EBV (16 h) or pretreated with PKC inhibitors for 30 min
(calphostin C (500 nM) or RO-31-8220 (500 nM))
before incubation with carboxylated fluoresceinated microspheres (at a
ratio of 12 particles/cell) at 37 °C for 2 h. The percentage of
cells having engulfed fluoresceinated beads was measured by flow
cytometry, as described under "Experimental Procedures." Similar
results were obtained in three independent experiments. p
values obtained from EBV-infected or PKC inhibitor-treated monocytes
were compared with mock control (arbitrarily set at 100%). * = p 0.05.
|
|
Impaired PKC Activity in EBV-infected
Monocytes--
Activation of PKC results in the phosphorylation of
various substrates. We first evaluated whether EBV infection affects
PKC activation following PMA stimulation of monocytes. This assay was
performed with cytosolic and membrane fractions obtained from uninfected or EBV-infected monocytes. As illustrated in Fig.
2A, the kinase activity of
cytosolic PKCs from EBV-infected monocytes, in the absence or in the
presence of PMA, is markedly decreased as compared with PKC activity
measured in cytosols of uninfected cells. Similar results were obtained
in testing PKC activity from membrane fractions (Fig. 2B).
In addition, PKC activity in membrane fractions from PMA-treated
monocytes was significantly suppressed by EBV (Fig. 2B).
These results suggest that EBV may affect PKC activity but also that
EBV can abrogate translocation of PKC from the cytosol to the membrane.
While PKC activity is reduced by EBV infection, the protein levels of
PKC were unaffected (data not shown). Thus, impairment of PKC activity
in cytosol and membrane fractions of infected monocytes does not result
from the degradation of the enzymes.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of EBV on PKC activity.
Cytosolic (A) and membrane (B) fractions (50 µg
of protein per sample) isolated from uninfected or EBV-infected
monocytes were assayed for PKC activity as described under
"Experimental Procedures." Results are representative of three
separate experiments, each carried out in triplicate. p
values were calculated after comparison between EBV with mock control
and EBV/PMA with PMA-treated cells. * = p 0.05.
|
|
EBV Infection Inhibits the Translocation of PKC and - from
Cytosol to Membrane Fractions in PMA-treated Monocytes--
Activation
of PKC involves its translocation from the cytosol to membranes. A
failure in PKC translocation prevents triggering of
PKC-dependent signaling cascade and impairs many biological functions. We next explored the impact of an EBV infection on the
translocation of PKC and - from unstimulated and PMA-stimulated monocytes. Uninfected and EBV-infected monocytes were stimulated or not
with PMA and proteins separated into cytosolic (C) and membrane (M) fractions. Western blot analysis indicates that
PKC remains sequestrated in the cytosolic fraction of EBV-infected monocytes treated with PMA, while translocation of PKC from the cytosol
to the membrane was easily detectable in uninfected monocytes (Fig.
3A). Similarly, EBV prevented
PKC (Fig. 3B) and PKC (data not shown) translocation
in PMA-activated monocytes, suggesting that this virus impairs the
translocation of various PKC isoforms. In addition, it should be noted
that the translocation process is not totally abolished by EBV, as
detectable PKC proteins in membrane fractions from EBV-infected
monocytes treated with PMA were observed. Interestingly, in
PMA-untreated cells, greater levels of PKC and - were observed in
the membrane fractions of EBV-infected monocytes compared with
uninfected ones (Fig. 3, A and B). This may be
explained by partial activation of PKC following binding of viral
particles to the monocyte membrane, events preceding the synthesis of
inhibitory viral proteins.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Inhibition of PMA-induced PKC translocation
in EBV-infected monocytes. Monocytes were infected with EBV
(105 transforming units) for 2 h at 37 °C.
Thereafter, cells were treated or not with PMA (100 ng/ml) at 37 °C
for the indicated times. Cells were washed, resuspended in 100 µl of
buffer, sonicated, and homogenates were ultracentrifuged to separate
cytosolic (C) and membrane (M) fractions. Equal
amounts of cytosolic and membrane protein levels in each samples were
loaded and separated by SDS-PAGE under reducing conditions, and
subcellular distribution of PKC (A) and PKC
(B) was visualized by Western blot using specific monoclonal
antibodies against each isoform of PKC. Intensity of each signal was
quantified by densitometry and presented in a histogram for each PKC
isoform. Results (mean ± S.D.) are expressed as PKC relative
intensity and are derived from three independent experiments.
|
|
EBV Disrupts the Subcellular Localization of the RACK1 Anchoring
Protein following PMA Treatment in Monocytes--
Binding of activated
PKC to RACK plays an important role in activation-induced translocation
of PKC. Since translocation of PKCs is strongly reduced in EBV-infected
monocytes, we evaluated the effects of EBV on the cellular localization
of RACK1 upon PMA stimulation. Similar to the results obtained with
PKC, the subcellular distribution of anchoring protein RACK1 is
affected in EBV-infected monocytes (Fig.
4). In contrast to uninfected cells,
large amounts of RACK1 protein remain sequestrated in the cytosolic
compartment of EBV-infected cells treated or not with PMA. These
results suggest that EBV inhibits the translocation process of RACK1 in
human monocytes.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
EBV alters subcellular localization of the
anchoring protein RACK1 following PMA treatment. Monocytes were
infected with EBV (105 transforming units) for
2 h at 37 °C as described under "Experimental Procedures."
Thereafter, cells were treated or not with PMA (100 ng/ml) at 37 °C
for 5 min. Cells were washed, resuspended in 100 µl of buffer,
sonicated, and homogenates were ultracentrifuged to separate cytosolic
(C) and membrane (M) fractions. Proteins were
separated by SDS-PAGE under reducing conditions, and subcellular
distribution of RACK1 was visualized by Western blot using polyclonal
anti-RACK1 antibodies. The lower panel represents
densitometric analysis expressed as RACK1 relative intensity (mean ± S.D.) derived from three independent experiments.
|
|
EBV-ZEBRA Affects PKC Translocation and Binds RACK1 in 293T
Cells--
ZEBRA has been linked with both the transactivation of
lytic EBV genes, which favors viral replication, as well as the
disruption of many cellular functions in B and T lymphocytes through
interactions with the p53 (26) and NF B p65 cellular proteins (27).
While the ZEBRA transcript could be detected in infected monocytes, its
translation product was not, suggesting that ZEBRA is expressed at low
levels in EBV-infected monocytes. For this reason, PKC activity and the
translocation process were evaluated in PMA-activated 293T cells
transfected with a ZEBRA expression vector. Similarly to EBV-infected
monocytes, ZEBRA-transfected 293T cells failed to adequately
translocate PKC following PMA treatment. In fact, the activity of
PKC is reduced by 37% in membrane fractions of pCMV-Z transfected-293T
cells following PMA treatment. Furthermore, PKC levels in membranes
from pCMV-Z transfected-293T cells stimulated with PMA are reduced as
compared with mock or control cells (Fig. 5B), suggesting that the
translocation process is affected by ZEBRA. However, since ZEBRA was
found to be widely distributed in transfected 293T cells
(e.g. cytosol and membrane), no significant changes were
observed in cytosolic and membrane pools of ZEBRA following PMA
treatment. Therefore, to evaluate whether the inhibition of PKC
translocation observed could be caused through a physical interaction
between ZEBRA and RACK 1, a co-immunoprecipitation approach was
considered. Interestingly, our results show that RACK1
co-immunoprecipitated ZEBRA, in support that both proteins physically
interact (Fig. 5C). We were not able to co-immunoprecipitate PKC / using anti-ZEBRA antibodies, suggesting that ZEBRA does not
bind to PKC. To ascertain that the ZEBRA-RACK1 interaction is not an
artifact resulting from ZEBRA overexpression, we carried out a similar
experiment using the immediate-early (IE1) gene of human herpesvirus-6.
293T cells were transfected with an expression vector for IE1 and
48 h later, IE1 was immunoprecipitated using rabbit anti-IE1
antibodies and protein A-Sepharose beads. No RACK1 protein could be
detected in the IE1 immunoprecipitate despite large quantitites of IE1
(data not shown). From these results we conclude that the interaction
of ZEBRA with RACK1 is specific and does not result from overexpression
of ZEBRA in transfected 293T cells.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
ZEBRA binds RACK1 and inhibits
PKC translocation in 293T cells. 293T
cells (1 × 106) were transfected with a plasmid
encoding for EBV ZEBRA or with the pHD1013 control vector as described
under "Experimental Procedures." Forty-eight hours later, cells
were treated or not with PMA (100 ng/ml) at 37 °C for 5 min. Cells
were washed, resuspended in 100 µl of buffer, sonicated, and
homogenates were ultracentrifuged to separate cytosolic (C)
and membrane (M) fractions. A, 15 µg of
membrane proteins isolated from pHD1013-transfected 293T or
pCMV-Z-transfected 293T stimulated with PMA were assayed for PKC
activity as described under "Experimental Procedures." p
values showing differences between ZEBRA-transfected cells
versus control cells are shown above the bars. * = p 0.05. B, cytosolic (C) and
membrane (M) proteins were separated by SDS-PAGE under
reducing conditions, and subcellular distribution of PKC was
visualized by Western blot using a anti-PKC monoclonal antibodies.
C, transfected 293T (3 × 106) were lysed
in RIPA-modified buffer, and 500 µg of whole proteins were used for
immunoprecipitation (IP) of ZEBRA, as described under
"Experimental Procedures." Immunoprecipitated proteins were
separated by SDS-PAGE and analyzed by Western blot (WB)
using either an anti-ZEBRA or anti-RACK1 antibodies. Results are
representative of two independent experiments.
|
|
 |
DISCUSSION |
It is well known that phagocytosis is crucial for the clearance of
pathogens and represents a key step in antigen presentation (28). This
process requires specific receptors on the cell surface (such as Fc and
complement receptors) and activation of protein tyrosine kinases as
well as PKCs, enzymes involved in foreign particles engulfment (28). We
thus analyzed the effect of EBV infection on the expression of specific
receptors and on the activation of protein kinases in monocytes. It has
been reported that some viruses such as MCMV (8), HIV (29), and more
recently EBV (6), have developed immunosuppressive strategies that
target phagocytosis (8, 29). Our results indicate that EBV does not
alter the expression of Fc (CD32, CD64) and complement (CR3) receptors
but instead alters phagocytosis through an impairment of PKC activity
in infected monocytes.
Since PKC isozymes carry out many cellular functions, it is not
surprising that viruses target these enzymes to disturb cell signaling.
A recent study reported that the HIV Nef protein interacts with PKC
and inhibits its translocation from the cytosol to the membrane
fraction (21, 22). Such a disruption may contribute to the impairment
of T cell function associated with HIV infection. Moreover, it was
demonstrated that NS3 protein of hepatitis C virus binds to PKC and
suppresses its enzymatic activity and its subcellular distribution upon
PMA stimulation (30, 31). According to Borowski et al. (30),
NS3 protein is able to stop PKC-mediated functions within intact cells,
supporting the possibility that NS3 disrupts PKC-mediated signal
transduction. Similar to hepatitis C virus and HIV, EBV affects the
activity of PKC in monocytes. Our results show that the PKC activity of
cytosolic and membrane-bound protein extracts of infected monocytes is
significantly lower than uninfected cells. Thus a reduction in PKC
activity may affect several biological functions of monocytes such as
phatocytosis, which are dependent on the activity of this enzyme. We
previously reported that EBV suppresses tumor necrosis factor and
COX-2 gene expression in monocytes (7, 32), the likely result of impaired NF B translocation (32) from cytosol to nucleus, regulatory events downstream of PKC activation (14, 33, 34). In contrast, D'Addario et al. (35) have reported that binding of
recombinant EBV gp350 envelope protein to monocytes leads to the
up-regulation of tumor necrosis factor gene expression via the
activation of NF- B, a process dependent of PKC and/or other kinase
activation. The system used by D'Addario and colleagues is somewhat
artificial and does not take into account the events occurring during
the infectious process such as viral protein synthesis. Binding of a
protein to the cell membrane may induce cell signaling, leading to the
activation of several cellular functions. Viral penetration and
replication involve synthesis of different proteins having the
potential to interact with host proteins and impair cellular function(s). We propose that infection of monocytes by EBV results in
the inhibition of PKC translocation and activation, which suppresses other PKC-related events, including tumor necrosis factor synthesis.
Translocation of enzymes from cytosol to particulate fractions upon
cell stimulation is specific and often regulated by anchoring proteins,
which bind selectively to enzymes allowing their subcellular relocalization. In the case of PKC, the anchoring protein RACK has been
identified to be mostly responsible for both specific localization and
the function of PKC isozymes (18, 36). RACKs are membrane-associated
proteins located in various subcellular compartments (18, 37). Through
co-factors such as calcium and diacylglycerol, RACK1 binds the active
form of PKCs and moves the enzymes toward specific location in the
cellular membrane following stimulation with agonist (18). Disruption
of protein-protein interactions between RACKs and PKCs prevents
agonist-mediated subcellular distribution of the enzymes and inhibits
their function (19). According to Stebbins et al. (38), when
the interaction between RACK1 and PKC II is prevented by blocking
peptides (which compete with PKC II for RACK1 binding), the
translocation of PKC II is inhibited and cellular functions are
affected. Our results show a reduced level of RACK1 in the membrane
compartment of PMA-activated EBV-infected monocytes, a likely
consequence for the reduction in PKC activity observed.
An EBV protein likely responsible for impaired PKC activation in
monocytes is ZEBRA (39). In contrast to B cells (40), EBV infection of
human monocytes is lytic with BZLF-1 transcripts, which encode for the
ZEBRA protein, expressed at early times (6). It has been reported that
complete activation of ZEBRA is dependent on Ser186
phosphorylation, an event catalyzed by PKC and related kinases (41).
Depending on the nature of PKC isoenzymes in the infected-cells, ZEBRA
could recruit cellular proteins, like RACK, for its own activity and/or
to affect cell signaling. Using the yeast two-hybrid system, EBV ZEBRA
was reported to bind RACK1 in vitro (23). However, this
study did not report the impact of ZEBRA expression on PKC activity.
ZEBRA can thus possibly disturb the interaction between RACK1 and
PKC / , resulting in an inhibition of PKC translocation. In fact,
our results indicate that the activity and the translocation of PKC
is affected in ZEBRA-expressing cells. However, PKC inhibition in
ZEBRA-transfected cells is less pronounced than in EBV-infected monocytes. This is possibly due to the very high PKC activity in 293T
cells or alternatively due to other PKC isoenzymes in 293T cells that
may be unaffected by ZEBRA. At the present time, we cannot exclude the
possible role of other EBV proteins, whose transcripts were detected in
infected monocytes (16). In fact, establishment of a lytic infection in
monocyte leads to the expression of several viral genes, which could
result in the inhibition of PKC activity. It is not surprising
that in PMA-stimulated ZEBRA-transfected 293T cells, the activity of
cytosolic PKCs is unaffected while that of membrane fractions is
reduced. Such results suggest that translocation of PKCs from cytosol
to membrane fractions is impaired in the presence of ZEBRA. Consistent
with this result is the analysis of PKC translocation in
ZEBRA-transfected 293T cells, which shows that translocation of this
isoenzyme from cytosolic to membrane fractions is disturbed in
PMA-stimulated cells, supporting the hypothesis that ZEBRA, through its
interaction with RACK1, impairs the translocation of PKCs. In agreement
with Baumann et al. (23), who suggested that RACK1 interacts
with ZEBRA, we have detected RACK1 in ZEBRA immunoprecipitates.
Furthermore, binding of RACK1 to ZEBRA could prevent the association of
RACK1 to PKC in the cytoplasm and inhibit the translocation of PKC to
membranes. Since RACKs are adaptor proteins that mediate recruitment of
various protein kinases (36, 37, 42), blocking activation of such protein may down-regulate phosphorylation of target protein and therefore cause impairment of various signaling pathways. The interaction between ZEBRA and RACK1 (a PKC anchoring protein) may
represent another strategy used by EBV to affect cellular functions of
human monocytes.
 |
FOOTNOTES |
*
This work was supported by a grant from the Canadian
Institutes of Health Research (CIHR) (to J. G.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
CIHR Young Investigator awardee.
¶
Senior Scholar from the Fonds de la Recherche en Santé
du Quebéc. To whom correspondence should be addressed:
Laboratory of Viral Immunology, Centre de Recherche en Rhumatologie et
Immunologie, CHUL Research Center (CHUQ), 2705 boul. Laurier, Rm. T
1-49, Sainte-Foy, Québec G1V 4G2, Canada. Tel.:
418-654-2772; Fax: 418-654-2127; E-mail:
Jean.Gosselin@crchul. ulaval.ca.
Published, JBC Papers in Press, April 23, 2002, DOI 10.1074/jbc.M109036200
2
Gravel, A., Gosselin, J., and Flamand, L. (2002) J. Biol. Chem. 277, 19679-19687.
 |
ABBREVIATIONS |
The abbreviations used are:
EBV, Epstein-Barr virus;
CMV, cytomegalovirus;
MCMV, murine cytomegalovirus;
HIV, human immunodeficiency virus;
PKC, protein kinase C;
RACK, receptor for activated C kinase;
PMA, phorbol 12-myristate
13-acetate.
 |
REFERENCES |
| 1.
|
Kelleher, C. A.,
Paterson, R. K.,
Dreyfus, D. H.,
Streib, J. E., Xu, J. W.,
Takase, K.,
Jones, J. F.,
and Gelfand, E. W.
(1995)
Virology
208,
685-695[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Guan, M.,
Romano, G.,
and Henderson, E. E.
(1998)
Anticancer Res.
18,
3171-3180[Medline]
[Order article via Infotrieve]
|
| 3.
|
Kanegane, H.,
Yachie, A.,
Miyawaki, T.,
and Tosato, G.
(1998)
Leuk. Lymphoma
29,
491-498[Medline]
[Order article via Infotrieve]
|
| 4.
|
Delsol, G.,
Meggetto, F.,
Brousset, P.,
Cohen-Knafo, E.,
al Saati, T.,
Rochaix, P.,
Gorguet, B.,
Rubin, B.,
Voigt, J. J.,
and Chittal, S.
(1993)
Am. J. Pathol.
142,
1729-1738[Abstract]
|
| 5.
|
Larochelle, B.,
Flamand, L.,
Gourde, P.,
Beauchamp, D.,
and Gosselin, J.
(1998)
Blood
92,
291-299[Abstract/Free Full Text]
|
| 6.
|
Savard, M.,
Bélanger, C.,
Tardif, M.,
Gourde, P.,
Flamand, L.,
and Gosselin, J.
(2000)
J. Virol.
74,
2612-2619[Abstract/Free Full Text]
|
| 7.
|
Gosselin, J.,
Menezes, J.,
D'Addario, M.,
Hiscott, J.,
Flamand, L.,
Lamoureux, G.,
and Oth, D.
(1991)
Eur. J. Immunol.
21,
203-208[Medline]
[Order article via Infotrieve]
|
| 8.
|
Price, P.,
Winter, J. G.,
Nikoletti, S.,
Hudson, J. B.,
and Shellam, G. R.
(1987)
J. Virol.
61,
3602-3606[Abstract/Free Full Text]
|
| 9.
|
Ravetch, J. V.,
and Kinet, J. P.
(1991)
Annu. Rev. Immunol.
9,
457-492[Medline]
[Order article via Infotrieve]
|
| 10.
|
Zheleznyak, A.,
and Brown, E. J.
(1992)
J. Biol. Chem.
267,
12042-12048[Abstract/Free Full Text]
|
| 11.
|
Karimi, K.,
and Lennartz, M. R.
(1995)
J. Immunol.
155,
5786-5794[Abstract]
|
| 12.
|
Keenan, C.,
and Kelleher, D.
(1998)
Cell Signal.
10,
225-232[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Allen, L. H.,
and Aderem, A.
(1995)
J. Exp. Med.
182,
829-840[Abstract/Free Full Text]
|
| 14.
|
Dieter, P.,
and Schwende, H.
(2000)
Cell Signal.
12,
297-302[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Keranen, L. M.,
Dutil, E. M.,
and Newton, A. C.
(1995)
Curr. Biol.
5,
1394-1403[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Mellor, H.,
and Parker, P. J.
(1998)
Biochem. J.
332,
281-292[Medline]
[Order article via Infotrieve]
|
| 17.
|
Parekh, D.,
Ziegler, W.,
and Parker, P.
(2000)
EMBO J.
19,
496-503[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Mochly-Rosen, D.,
Khaner, H.,
and Lopez, J.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3997-4000[Abstract/Free Full Text]
|
| 19.
|
Mochly-Rosen, D.,
and Gordon, A. S.
(1998)
FASEB J.
12,
35-42[Abstract/Free Full Text]
|
| 20.
|
Korchak, H. M.,
and Kilpatrick, L. E.
(2001)
J. Biol. Chem.
276,
8910-8917[Abstract/Free Full Text]
|
| 21.
|
Gallina, A.,
Rossi, F.,
and Milanesi, G.
(2001)
Virology
283,
7-18[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Smith, B. L.,
Krushelnycky, B. W.,
Mochly-Rosent, D.,
and Berg, P.
(1996)
J. Biol. Chem.
271,
16753-16757[Abstract/Free Full Text]
|
| 23.
|
Baumann, M.,
Gires, O.,
Kolch, W.,
Mischak, H.,
Zeidler, R.,
Pich, D.,
and Hammerschmidt, W.
(2000)
Eur. J. Biochem.
267,
3891-3901[Medline]
[Order article via Infotrieve]
|
| 24.
|
Beaulieu, A. D.,
Paquin, R.,
and Gosselin, J.
(1995)
Blood
86,
2789-2798[Abstract/Free Full Text]
|
| 25.
|
Brown, E. J.
(1991)
Curr. Opin. Immunol.
3,
76-82[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Dreyfus, D. H.,
Nagasawa, M.,
Kelleher, C. A.,
and Gelfand, E. W.
(2000)
Blood
96,
625-634[Abstract/Free Full Text]
|
| 27.
|
Dreyfus, D. H.,
Nagasawa, M.,
Pratt, J. C.,
Kelleher, C. A.,
and Gelfand, E. W.
(1999)
J. Immunol.
163,
6261-6268[Abstract/Free Full Text]
|
| 28.
|
Aderem, A.,
and Underhill, D. M.
(1999)
Annu. Rev. Immunol.
17,
593-623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Kent, S. J.,
Stent, G.,
Sonza, S.,
Hunter, S. D.,
and Crowe, S. M.
(1994)
Clin. Exp. Immunol.
95,
450-454[Medline]
[Order article via Infotrieve]
|
| 30.
|
Borowski, P.,
zur Wiesch, J.,
Resch, K.,
Feucht, H.,
Laufs, R.,
and Schmitz, H.
(1999)
J. Biol. Chem.
274,
30722-30728[Abstract/Free Full Text]
|
| 31.
|
Borowski, P.,
Resch, K.,
Schmitz, H.,
and Heiland, M.
(2000)
Biol. Chem.
381,
19-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Savard, M.,
Bélanger, C.,
Tremblay, M. J.,
Dumais, N.,
Flamand, L.,
Borgeat, P.,
and Gosselin, J.
(2000)
J. Immunol.
164,
6467-6473[Abstract/Free Full Text]
|
| 33.
|
Giroux, M.,
and Descoteaux, A.
(2000)
J. Immunol.
165,
3985-3991[Abstract/Free Full Text]
|
| 34.
|
Mestre, J. R.,
Mackrell, P. J.,
Rivadeneira, D. E.,
Stapleton, P. P.,
Tanabe, T.,
and Daly, J. M.
(2001)
J. Biol. Chem.
276,
3977-3982[Abstract/Free Full Text]
|
| 35.
|
D'Addario, M.,
Ahmad, A.,
Morgan, A.,
and Menezes, J.
(2000)
J. Mol. Biol.
298,
765-778[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Ron, D.,
Chen, C. H.,
Caldwell, J.,
Jamieson, L.,
Orr, E.,
and Mochly-Rosen, D.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
839-843[Abstract/Free Full Text]
|
| 37.
|
Liliental, J.,
and Chang, D. D.
(1998)
J. Biol. Chem.
273,
2379-2383[Abstract/Free Full Text]
|
| 38.
|
Stebbins, E. G.,
and Mochly-Rosen, D.
(2001)
J. Biol. Chem.
276,
29644-29650[Abstract/Free Full Text]
|
| 39.
|
Dillner, J.,
and Kallin, B.
(1988)
Adv. Cancer Res.
50,
95-158[Medline]
[Order article via Infotrieve]
|
| 40.
|
Baumann, M.,
Mischak, H.,
Dammeier, S.,
Kolch, W.,
Gires, O.,
Pich, D.,
Zeidler, R.,
Delecluse, H. J.,
and Hammerschmidt, W.
(1998)
J. Virol.
72,
8105-8114[Abstract/Free Full Text]
|
| 41.
|
Bornancin, F.,
and Parker, P. J.
(1997)
J. Biol. Chem.
272,
3544-3549[Abstract/Free Full Text]
|
| 42.
|
Chang, B. Y.,
Chiang, M.,
and Cartwright, C. A.
(2001)
J. Biol. Chem.
276,
20346-20356[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Warwar, S. Efendic, C.-G. Ostenson, E. P. Haber, E. Cerasi, and R. Nesher
Dynamics of Glucose-Induced Localization of PKC Isoenzymes in Pancreatic {beta}-Cells: Diabetes-Related Changes in the GK Rat
Diabetes,
March 1, 2006;
55(3):
590 - 599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. O. Guerreiro-Cacais, L. Li, D. Donati, M. T. Bejarano, A. Morgan, M. G. Masucci, L. Hutt-Fletcher, and V. Levitsky
Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication
J. Gen. Virol.,
October 1, 2004;
85(10):
2767 - 2778.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Deutsch, A. Cohen, G. Kazimirsky, S. Dovrat, H. Rubinfeld, C. Brodie, and R. Sarid
Role of Protein Kinase C {delta} in Reactivation of Kaposi's Sarcoma-Associated Herpesvirus
J. Virol.,
September 15, 2004;
78(18):
10187 - 10192.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. Kelly, D. B. Stetson, and R. M. Locksley
Leishmania major LACK Antigen Is Required for Efficient Vertebrate Parasitization
J. Exp. Med.,
December 1, 2003;
198(11):
1689 - 1698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Shaw, X. Wang, H. Redd, G. D. Alexander, C. M. Isales, and M. B. Marrero
High Glucose Augments the Angiotensin II-induced Activation of JAK2 in Vascular Smooth Muscle Cells via the Polyol Pathway
J. Biol. Chem.,
August 15, 2003;
278(33):
30634 - 30641.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|